Colicinogeny in local isolates of salmonellae and plasmid transfer studies
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
12800513
DOI
10.1007/bf02930966
Knihovny.cz E-resources
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Drug Resistance, Bacterial MeSH
- Colicins biosynthesis MeSH
- Conjugation, Genetic * MeSH
- Chickens microbiology MeSH
- Humans MeSH
- Lipopolysaccharides metabolism MeSH
- Poultry Diseases microbiology MeSH
- Plasmids genetics MeSH
- Bacterial Outer Membrane Proteins metabolism MeSH
- Salmonella classification genetics isolation & purification metabolism MeSH
- Salmonella Infections microbiology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Colicins MeSH
- Lipopolysaccharides MeSH
- Bacterial Outer Membrane Proteins MeSH
Colicinogeny was determined in local isolates of S. typhimurium and S. enteritidis. Fourteen out of 35 S. typhimurium isolates of hospital origin were colicin producers whereas only one chicken isolate out of 82 S. enteritidis isolates of various origin (human, chicken or egg) produced colicin. A colicin producing, cephalothin (Cpt)- and piperacillin (Prl)-resistant local isolate of Salmonella havana (H32) harbored 4 plasmids of 54.0, 28.4, 2.7 and 1.9 kb. Upon curing its plasmids, the strain lost the ability to produce colicin and resistance to antibiotics and no longer expressed smooth lipopolysaccharide (LPS). The outer membrane protein (OMP) of 34.6 kDa was also lost. Using nalidixic acid (Nal)-resistant mutant of the cured strain in conjugation experiments, 10 out of 27 transconjugants were found to be resistant to Nal and Prl, 10 were resistant to Nal and Cpt and 7 showed Nal, Prl and Cpt resistance. Cpt and Prl resistance were determined by 54.0 and 28.4 kb plasmids, respectively. There was no direct correlation between plasmid contents and colicinogeny, LPS and OMP profiles.
See more in PubMed
Microb Pathog. 1989 Sep;7(3):195-202 PubMed
Epidemiol Infect. 1998 Oct;121(2):303-7 PubMed
Int J Clin Pharmacol Ther Toxicol. 1986 Aug;24(8):433-7 PubMed
J Pathol Bacteriol. 1966 Jul;92(1):107-38 PubMed
Antimicrob Agents Chemother. 2000 Oct;44(10):2777-83 PubMed
J Med Microbiol. 1992 Aug;37(2):104-8 PubMed
J Bacteriol. 1981 Mar;145(3):1365-73 PubMed
J Appl Bacteriol. 1990 Jan;68(1):5-16 PubMed
Vet Microbiol. 2000 Jul 3;75(1):73-82 PubMed
Infect Immun. 1983 Jan;39(1):315-35 PubMed
Infect Immun. 1985 Apr;48(1):175-82 PubMed
Microb Pathog. 1988 May;4(5):385-91 PubMed
J Bacteriol. 1983 Apr;154(1):269-77 PubMed
Vet Res Commun. 1997 Aug;21(6):409-20 PubMed
Anal Biochem. 1982 Jan 1;119(1):115-9 PubMed
